GLP-1 is a peptide hormone released in the small intestine and the colon within minutes of ingesting food
Far from being a single procedural step, a FIH trial is built on a broad body of scientific, regulatory and operational work designed to ensure that the transition from preclinical research to human investigation takes place within a rigorous framework focused on safety, quality and evidence generation
You can still take the medicationit won't be harmful if you take it later in the day
Clinicians play a pivotal role in helping patients translate the promise of GLP-1 medications into lasting health
[DOI] [PubMed] [Google Scholar] 63.Sikiri P., Seiwerth S., Deskovi S., Grabarevi Z., Marovi A., Rucman R., Petek M., Konjevoda P., Jadrijevi S., Sosa T., et al